Orchard Therapeutics plc (ORTX)

NASDAQ: ORTX · IEX Real-Time Price · USD
0.566
-0.034 (-5.64%)
At close: Jan 27, 2023, 3:59 PM
0.560
-0.006 (-1.06%)
After-hours: Jan 27, 2023, 7:52 PM EST
-5.64%
Market Cap 71.71M
Revenue (ttm) 16.15M
Net Income (ttm) -179.13M
Shares Out 126.69M
EPS (ttm) -1.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 463,711
Open 0.580
Previous Close 0.600
Day's Range 0.540 - 0.600
52-Week Range 0.360 - 1.230
Beta 0.69
Analysts Buy
Price Target 3.40 (+500.71%)
Earnings Date n/a

About ORTX

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinica... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Prof. Bobby Gaspar Ph.D., M.D.
Employees 259
Stock Exchange NASDAQ
Ticker Symbol ORTX
Full Company Profile

Financial Performance

In 2021, ORTX's revenue was $1.68 million, a decrease of -35.45% compared to the previous year's $2.60 million. Losses were -$144.58 million, -4.87% less than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for ORTX stock is "Buy." The 12-month stock price forecast is $3.4, which is an increase of 500.71% from the latest price.

Price Target
$3.4
(500.71% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Orchard Therapeutics Highlights Recent Progress Across HSC Gene Therapy Portfolio and Outlines Key 2023 Milestones

Libmeldy® revenue totaled $5.8M in Q4 2022 and $18.8M for the full year with commercial expansion activities continuing in Europe

2 weeks ago - GlobeNewsWire

Orchard Therapeutics Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IH

Global registrational trial expected to commence in the second half of 2023 Global registrational trial expected to commence in the second half of 2023

3 weeks ago - GlobeNewsWire

Orchard Therapeutics Announces Promising Early Neurocognitive Outcomes from Ongoing Proof-of-concept Study of OTL-201 in MPS-IIIA

All patients achieved sustained engraftment and supraphysiological SGSH enzyme levels with median 1.5 years follow-up

1 month ago - GlobeNewsWire

Orchard Therapeutics Announces Swissmedic Validation of the Marketing Authorization Application for Libmeldy (atidarsagene autotemcel)

BOSTON and LONDON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced its marketing authorization application (MAA) for Libmeldy® (ati...

2 months ago - GlobeNewsWire

Orchard Therapeutics Reports Third Quarter 2022 Financial Results and Reviews Recent Business Highlights

Libmeldy ® product sales totaled $4.8M in Q3 and $13.0M YTD with market expansion activities continuing in Europe

2 months ago - GlobeNewsWire

Orchard Therapeutics to Present at Multiple Investor Conferences in November 2022

BOSTON and LONDON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present at the followin...

2 months ago - GlobeNewsWire

Orchard Therapeutics to Webcast Conference Call of Third Quarter 2022 Financial Results

BOSTON and LONDON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on...

2 months ago - GlobeNewsWire

Orchard Therapeutics Announces First Neurocognitive Data from OTL-201 Study in MPS-IIIA Accepted for Oral Presentation at ASH 2022

Company to host KOL conference call and webcast on Monday, December 12 at 5:00 p.m. EST Company to host KOL conference call and webcast on Monday, December 12 at 5:00 p.m. EST

3 months ago - GlobeNewsWire

Orchard Announces Multiple Presentations at 2022 ESGCT Annual Congress Showing the Potential of HSC Gene Therapy in Several Therapeutic Areas

Clinical and pre-clinical data from across the company's portfolio will be featured in four oral and six poster presentations

3 months ago - GlobeNewsWire

Orchard Therapeutics Announces Multiple Presentations at 2022 SSIEM Annual Symposium Highlighting Neurometabolic Disease Portfolio

BOSTON and LONDON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced seven presentations from across its neurometabolic portfolio wil...

5 months ago - GlobeNewsWire

Orchard Therapeutics Reports Second Quarter 2022 Financial Results and Reviews Recent Business Highlights

Additional Libmeldy ® reimbursement discussions advancing across Europe with product sales totaling $3.1M in Q2 and $8.2M YTD

6 months ago - GlobeNewsWire

Orchard Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Commercial Progress

Product sales for Libmeldy totaled $5.1M for the first two commercial patients treated in Q1 2022

9 months ago - GlobeNewsWire

Orchard Therapeutics Announces Presentations at ASGCT 2022 Showcasing Potential of HSC Gene Therapy in Neurodegenerative Disorders and Beyond

BOSTON and LONDON, May 10, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today outlined seven presentations from across its platform to be featured at the...

9 months ago - GlobeNewsWire

Orchard Therapeutics to Webcast Conference Call of First Quarter 2022 Financial Results

BOSTON and LONDON, May 05, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on ...

9 months ago - GlobeNewsWire

Orchard Therapeutics Announces Agreement Enabling Access and Reimbursement for Libmeldy for All Eligible MLD Patients in Germany

BOSTON and LONDON, May 02, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced it has reached an agreement with Gesetzliche Krankenversicherung ...

9 months ago - GlobeNewsWire

Orchard Therapeutics Announces Reimbursement Agreement Making Libmeldy Available for All Eligible MLD Patients in Italy

BOSTON and LONDON, April 11, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced it has reached another historic reimbursement agreement with th...

10 months ago - GlobeNewsWire

Orchard Therapeutics Extends Runway into 2024, Focusing HSC Gene Therapy Platform Exclusively on Severe Neurometabolic Diseases and Research Platform

Libmeldy European launch momentum building with multiple MLD patients treated and strong recognition of value proposition; U.S. BLA filing of OTL-200 on track for late 2022 / early 2023

10 months ago - GlobeNewsWire

Orchard Therapeutics to Webcast Conference Call of Fourth Quarter and Fiscal Year 2021 Financial Results

BOSTON and LONDON, March 24, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast o...

11 months ago - GlobeNewsWire

Orchard Therapeutics to Present at Multiple Investor Conferences in March 2022

BOSTON and LONDON, March 03, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present at the followi...

11 months ago - GlobeNewsWire

Orchard Therapeutics Announces Multiple Presentations at WORLDSymposium™ 2022

BOSTON and LONDON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today outlined five upcoming presentations from across its neurodegenerative por...

1 year ago - GlobeNewsWire

Orchard Therapeutics Announces Historic Agreement Making Libmeldy Available by NHS England for MLD Patients

First-ever lentiviral hematopoietic stem cell gene therapy approved for reimbursement by NHS England

1 year ago - GlobeNewsWire

Orchard Therapeutics Announces Publication in The Lancet of Long-term Clinical Outcomes with Libmeldy for the Treatment of Children with Early-onset MLD

Administration of one-time hematopoietic stem cell (HSC) gene therapy resulted in sustained, clinically meaningful benefits by preserving cognitive function and motor development in most patients

1 year ago - GlobeNewsWire

Orchard Therapeutics Announces Recent Commercial and Regulatory Progress for Late-stage HSC Gene Therapy Programs and Outlines Key 2022 Milestones

Launch Momentum Building for Libmeldy® in Europe with Health Technology Assessments Progressing Favorably and Treatment Underway for Multiple Commercial Patients

1 year ago - GlobeNewsWire

Orchard Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

BOSTON and LONDON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the virtual 40th Ann...

1 year ago - GlobeNewsWire

Orchard Therapeutics Announces New England Journal of Medicine Publication of Interim Proof-of-concept Study Results of OTL-203 for Hurler Syndrome

100 percent overall survival with median follow-up of two years post-treatment with HSC gene therapy

1 year ago - GlobeNewsWire